BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10215835)

  • 1. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography.
    Lucas JD; O'Doherty MJ; Cronin BF; Marsden PK; Lodge MA; McKee PH; Smith MA
    Br J Surg; 1999 Apr; 86(4):550-6. PubMed ID: 10215835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
    Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
    J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
    Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
    Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?
    Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Schultheiss M; Kotzerke J; Reske SN
    Eur J Nucl Med; 1999 Jun; 26(6):599-605. PubMed ID: 10369945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
    Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
    Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
    Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas.
    Tateishi U; Hosono A; Makimoto A; Sakurada A; Terauchi T; Arai Y; Imai Y; Kim EE
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):608-12. PubMed ID: 17805034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET).
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Mechtersheimer G; Hinz U; Willeke F; Cardona S; Attigah N; Strauss LG; Herfarth C; Lehnert T
    Anticancer Res; 2001; 21(5):3609-14. PubMed ID: 11848531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
    Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
    J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
    Bredella MA; Caputo GR; Steinbach LS
    AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoma.
    Ceyssens S; Stroobants S
    Methods Mol Biol; 2011; 727():191-203. PubMed ID: 21331935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.
    Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Hasegawa T
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):683-91. PubMed ID: 16506050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours?
    Hain SF; O'Doherty MJ; Bingham J; Chinyama C; Smith MA
    Nucl Med Commun; 2003 Nov; 24(11):1139-43. PubMed ID: 14569167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.
    Benz MR; Dry SM; Eilber FC; Allen-Auerbach MS; Tap WD; Elashoff D; Phelps ME; Czernin J
    J Nucl Med; 2010 Aug; 51(8):1174-81. PubMed ID: 20660389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.
    Cardona S; Schwarzbach M; Hinz U; Dimitrakopoulou-Strauss A; Attigah N; Mechtersheimer section sign G; Lehnert T
    Eur J Surg Oncol; 2003 Aug; 29(6):536-41. PubMed ID: 12875862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.
    Griffeth LK; Dehdashti F; McGuire AH; McGuire DJ; Perry DJ; Moerlein SM; Siegel BA
    Radiology; 1992 Jan; 182(1):185-94. PubMed ID: 1727280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.